Antibodies or antibody derivatives that bind to prognostic or therapeutically relevant proteins or receptors overexpressed on tumor cells (PD-L1, EGFR, VEGF-A, etc.)or immune cells (PD-1, CTLA-4, CD8, etc.)are gaining use in oncology applications. This evidence concerns the gene CD8A and neoplasm.